Citations

Clear

183 citation(s) found for "Yen, AW".

Lower Lobe Mucus Plug Distribution is Associated With Increased Risk for Future Acute Exacerbations Among Tobacco-exposed Persons
Mettler, S.K., Campo, M. Iturrioz, Yen, A., Sonavane, S., Wang, Wei , Cho, M.H. , Mettler, Sofia K. , Wan, Emily S. , Borgaonkar, Ruchita , Nardelli, Pietro , Grumley, Scott , Estépar, R. San José , Díaz, Alejandro A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2944-A2944

10.1164/ajrccm.2025.211.abstracts.a2944 Get It

Abstract Introduction / Rationale Mucus plugs (MPs) on chest computed tomography (CT) are associated with increased respiratory symptoms, worse lung function, and elevated mortality and acute exacerbations among individuals with GOLD2-4 COPD. Whether mucus plug distribution in the upper versus lower lobes differentially impacts future acute exacerbations (AEs) has been incompletely explored. Methods Data from current and former tobacco users, ages 40-80, with ≥10 pack-years, at the enrollment visit in COPDGene were analyzed. MPs were visually-assessed on chest CTs using a sequential reading system; the MP score was calculated as the number of bronchopulmonary segments with plugs (range 0-18). Among subjects with MPs, the percent of lower lobe MPs (%LLMPs) was calculated as the number of bronchopulmonary segments in the right and left lower lobes divided by the total number of bronchopulmonary segments (range 0-100%). Moderate-to-severe AEs were assessed prospectively biannually for up to 15.5 years. Zero-inflated Poisson regression, adjusting for age, sex, BMI, race, smoking status, pack-years, FEV1% predicted, history of AEs (year prior to enrollment), and clinical center assessed the relationship between %LLMPs, total MPs, and prospective AEs; duration of follow-up was included as the offset. Subgroup analyses by lung function category (GOLD0, GOLD 1-4 COPD, and Preserved Ratio Impaired Spirometry, PRISm) were also performed using the same model. Results Among 10,198 tobacco-exposed individuals, 9,406 subjects (mean age 59.7±9.0, 53.4% male, 68% non-Hispanic white) had chest CT scans scored for MPs. The overall prevalence of MP>0 was 30.4%, with an average MP score of 0.78±1.88 and average %LLMP of 48%±39%. The prevalence of MPs varied by lung function category (20.1% GOLD0, 26.2% PRISm, 40.8% COPD) as did the mean MP score (0.28±0.93 GOLD0, 0.49±1.38 PRISm, 1.30±2.42 COPD) (Figure 1). The %LLMP also varied by lung function category (33%±39% GOLD0, 38%±37% PRISm, 57%±37% COPD). Among subjects with MPs>0 (n=2,857), higher %LLMP was associated with a significantly increased risk for future AEs (adjusted rate ratio (aRR) [95%CI]= 1.11[1.05-1.17]; Figure 1). Subgroup analyses by lung function category supported a significant association between increased %LLMP and future AEs in GOLD0 (aRR 1.45 [1.25-1.69]), but not in the COPD or PRISm subgroups (Figure 1). Conclusions A higher proportion of lower lobe mucus plugs is significantly associated with increased risk for future AEs among tobacco-exposed persons. Despite having the lowest burden of MPs, the highest risk for prospective AEs with increasing %LLMP was observed in the subgroup with normal spirometry (GOLD0).
Effect of very preterm delivery on outcomes following in utero spina bifida repair
Zaretsky, Michael V. , Anadkat, Jagruti , Bennett, Kelly, Blumenfeld, Yair J. , Buchanan, Christina , Clifford, Caitlin , Crombleholme, Timothy M., Emery, Stephen P. , Goodnight, William , Lee, Hanmin , Lillegard, Joseph B. , Luks, François I. , Moldenhauer, Julie S. , Schenone, Mauro , Skupski, Daniel, Wagner, Amy J., Elbabaa, Samer K. , Lim, Foong‐Yen Y. , Lijewski, Virginia A. , Miller, Jena L. , Moehrlen, Ueli , Moon‐Grady, Anita J. , Schenone, Mauro H , Shaaban, Aimen F. , Tsao, KuoJen , Van Mieghem, Tim

Mayo Clinic

Pregnancy | April 30, 2025 | Volume: 1 | Issue: 3 | Pages: No page available

10.1002/pmf2.70027 | PMID 40963542 Get It

Abstract Objective In utero fetal spina bifida repair decreases the risk for cerebrospinal fluid (CSF) diversion including ventriculoperitoneal (VP) shunt placement, reverses hindbrain herniation, and improves motor function with a higher likelihood of independent ambulation. Unfortunately, in utero surgery can be complicated by preterm delivery. The goal of this study was to compare pregnancy and neonatal outcomes between individuals who delivered very preterm, and those who delivered later in gestation following in utero spina bifida repair. Methods Data from the North American Fetal Therapy Network Fetal Myelomeningocele Consortium Registry collected from 2011 to 2024 were analyzed. Three cohorts of patients were categorized by gestational age at delivery and compared: <30 weeks, 30–34 weeks, and >34 weeks. Comparisons between groups for maternal and delivery outcomes were completed for the entire cohort and then analyzed for those with available CSF diversion data up to 1 year of life. Chi‐square or Fisher's exact tests were used to compare categorical variables, and Kruskal–Wallis tests were used to determine if there are significant differences between the distributions of the three groups. A p ‐value <0.05 was considered significant. Results A total of 1213 patients were analyzed (<30 weeks, n = 111 [9.2%]; 30–34 weeks, n = 323 [26.6%]; >34 weeks, n = 779 [64.2%]). Overall fetal and neonatal mortality was 2.2%, 85% of which occurred in the <30‐week cohort, where perinatal mortality was 21%. Latency from fetal surgery to delivery averaged 2.1 weeks for the <30‐week group. Rates of abruption, chorioamnionitis, and spontaneous labor were higher in the <30‐week group compared to later gestational age cohorts. Neonatal morbidity was also significantly higher in the <30‐week cohort for sepsis, apnea, respiratory distress, patent ductus arteriosus, intraventricular hemorrhage, and periventricular leukomalacia in the <30‐week cohort. CSF diversion data were available for 677 neonates (<30 weeks, n = 53; 30–34 weeks, n = 186; >34 weeks, n = 438). There was no significant difference in VP shunt placement between the different gestational age groups. Conclusion Very preterm birth following in utero spina bifida repair results in significant perinatal mortality and neonatal morbidity. Delivery prior to 30 weeks of gestation occurs in 9% of patients after in utero spina bifida repair, resulting in a 21% perinatal mortality rate. However, even among those who delivered very preterm, a reduction in VP shunt rates, a benefit of in utero repair, appears to be preserved. Further data are warranted to assess the impact of prematurity following in utero surgery on ambulation and developmental outcomes.
Abstract 2470: Transforming cancer diagnosis with digital chemical pathology
Oh, Ji-Hun , Liu, Yen‐Ting , Ho, Ruo-Jing , Sharma, Ishaan , Orr, Andres C., Tamonis, Mykolas, Cheville, John C. , Falahkheirkhah, Kianoush , Yeh, Kevin L. , Confer, Matthew P. , Bhargava, Rohit

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2470-2470

10.1158/1538-7445.am2025-2470 Get It

Pathology remains a labor-intensive discipline, relying on workflows rooted in practices established over a century ago. Despite incremental technological advancements, the diagnostic process—from tissue preparation to interpretation—still heavily depends on thinly sliced tissue sections stained and examined under brightfield microscopy by skilled pathologists. Difficult cases often necessitate iterative staining or complex immunohistochemistry (IHC) analyses. However, the recent emergence of machine learning (ML) presents an opportunity to revolutionize traditional diagnostic workflows. One promising advancement is Digital Chemical Pathology (DCP), a paradigm that combines modern ML algorithms with infrared (IR) imaging to streamline pathology and enhance diagnostic accuracy. Infrared wavelengths inherently align with molecular vibrational frequencies, providing intrinsic contrast based on the chemical composition of samples. Mid-IR spectroscopic microscopes leverage this principle to spatially resolve molecular distributions at the pixel level, creating "chemical fingerprints" that ML algorithms can correlate with cellular identities and disease states. Recent advancements, particularly the development of broadly tunable quantum cascade lasers (QCLs), have enabled faster IR imaging, paving the way for clinical applications of IR spectroscopic microscopes. In this research, we demonstrate the potential of DCP using frozen tissue samples. Our approach focuses on two core tasks: (1) virtual staining, translating IR images into realistic, stained images interpretable by pathologists, and (2) tissue segmentation, enabling the automated detection of cancer and the distinction between normal and cancerous tissues. Furthermore, we incorporate statistical safety algorithms to generate uncertainty maps, ensuring the reliability of predictions. Our findings highlight that the integration of IR imaging and ML can facilitate automated diagnostics, providing pathologists with powerful tools for enhanced healthcare delivery. By leveraging DCP, we aim to modernize pathology workflows, reduce diagnostic turnaround times, and improve patient outcomes through precise and efficient analysis. Citation Format: Kianoush Falahkheirkhah, Kevin Yeh, Ji-Hun Oh, Yen-Ting Liu, Ruo-Jing Ho, Ishaan Sharma, Matthew Confer, Andres Orr, Mykolas Tamonis, John Cheville, Rohit Bhargava. Transforming cancer diagnosis with digital chemical pathology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2470.
EP5.19 CT Morphological Differences Based On Age and Sex for Patients with Symptomatic Femoroacetabular Impingement
O’Connor, Kyle P. , Grammatopoulos, George, Nepple, Jeffrey J. , Group, ANCHOR Study, Clohisy, John C, O’Connor, Kyle, Grammatopoulos, George , Krych, Aaron J. , Belzile, Etienne Louis , Yen, Yi‐Meng , Group, ANCHOR Study, Clohisy, John C

Mayo Clinic

Journal of Hip Preservation Surgery | March 30, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i87-i87

10.1093/jhps/hnaf011.281 Get It

Abstract Introduction: Low-dose computed tomography (CT) has been increasingly utilized in FAI due to its improved ability to characterize the complex and variable hip morphologies of FAI patients, compared to plain radiographs. This study defined FAI morphology between females and males as well as across adolescents, young adults, and older adults. Methods: A multi-center, prospective cohort of FAI patients undergoing primary arthroscopy was performed. Patients 14-45 years of age with idiopathic FAI were included. Low-dose CT was used for preoperative planning. Analysis focused on acetabular and femoral morphology and the differences between females/males and adolescents (A,14-18.9)/young adults (Y,19-24.9)/older adults (O,25+). Adolescents were the reference group during analysis. Results: There were 604 patients with CT data. Mean age was 24.9 years with 55.9% female. Males had more anterosuperior coverage (i.e. 64.2% vs 62.5% at 1:00), lower version (14.1° vs 18.0°), smaller femoral neck-shaft angles (130.9° vs 133.4°), and larger alpha angles (i.e. 72.1° vs 58.6° at 1:00) compared to females. Multivariable analysis demonstrated that females had associations with more femoral anteversion (OR: 1.05,CI: 1.03-1.07) and larger femoral neck-shaft angles (OR: 1.11,CI: 1.06-1.16). Males has associations with larger alpha angles at 1:00 (OR: 1.05,CI: 1.02-1.07) and 1:30 (OR: 1.03,CI: 1.00-1.06) as well as radial coverage at 1:00 (OR: 1.18,CI: 1.11-1.26). For females, adolescents had slightly less radial coverage at 2:00 (49.9%) compared to young (51.2%) and older adults (51.4%). Femoral neck-shaft angle decreased across age groups (A: 134.4°,Y: 133.0°,O: 132.7°). Alpha angles increased at 2:00 with age (A:54.6°,Y:55.3°,O:58.7°). Multivariable analysis had femoral neck-shaft angle decreasing for young (OR: 0.932,CI: 0.87) and older adults (OR:0.92,CI: 0.86-0.98) and it also had alpha angle at 1:15 increasing for young adults (OR: 1.03,CI: 1.00-1.06) and older adults (OR: 1.03,CI: 1.01-1.06). Males did not have any appreciable differences alpha angles, femoral version, or acetabular coverage across age groups. Conclusion: Differences in morphology identified on CT exist between females and males as well as across age groups for females. These differences may offer insight into disease pathomechanics between these patient populations. Further studies should confirm these findings and look at how they affect patient outcomes after treatment.
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program
Hanauer, Stephen B. , Torres, Esther A. , Aragon-Han, Patricia, Chapman, J. Casey, Arai, Ronen, Butnariu, Mandalina, Lee, Thomas C., Rabizadeh, Shervin , Check, Morgan, Hashash, Jana G. , Meister, Thomas, Yen, Eugene F. , Kinnucan, Jami , Ziring, David , Shaposhnikov, Rimma, Sinh, Preetika , Qazi, Taha , Yarur, Andrés , Monzur, Farah , Abraham, Bincy , Lee, Thomas C , Hashash, Jana G , Sinh, Preetika , Abraham, Bincy P , Yarur, Andres J , Hanauer, Stephen B , Swaminath, Arun C. , Butnariu, Mandalina, Barrett, Terrence A. , Stein, Daniel J., Shaposhnikov, Rimma, Dervieux, Thierry

Mayo Clinic

Pharmaceutics | March 28, 2025 | Volume: 17 | Issue: 4 | Pages: 428

10.3390/pharmaceutics17040428 | PMID 40284422 Get It

Background/Objectives: This study aimed to establish the clinical utility of a therapeutic drug monitoring (TDM)-supported, model-informed precision dosing (MIPD) approach (precision-guided dosing [PGD]) by assessing the impact of pharmacokinetic (clearance [CL]) and clinical laboratory parameters on adalimumab (ADA) dosage adjustments during maintenance therapy for inflammatory bowel disease (IBD). Methods: In the EMPOWER study, blood was collected at any time post-ADA injection. Pharmacokinetic (PK) testing was conducted in an accredited lab. Inputs for the PGD test included ADA concentrations, antibodies to ADA, albumin levels, and the current dosing regimen. CL was calculated using nonlinear mixed-effect models. Results were reported to health care providers (HCPs) within 3 days. HCPs’ treatment decisions were recorded and classified as treatment reduction, continuation, intensification, or ADA discontinuation. The physician global assessment (PGA) of disease activity was collected. Relationships between drug concentrations, CL, disease activity, and physician decision-making were assessed using logistic regression. Results: A total of 213 cases were assessed by 21 HCPs. ADA treatment was intensified in 24% and discontinued in 13% of cases. An ADA concentration ≤ 10 μg/mL was associated with a 23.7-fold and 3.0-fold higher likelihood of therapy intensification and PGA > 0, respectively, compared to concentrations > 10 μg/mL. An ADA concentration < 5 μg/mL was associated with a 3.3-fold higher likelihood of treatment discontinuation. CL ≥ 0.318 L/day was associated with a 10.4-fold higher likelihood of therapy intensification. Higher CL (>0.8 L/day) was associated with a 3.5-fold and 4.2-fold higher likelihood of treatment discontinuation and PGA > 0, respectively. Conclusions: PGD enables earlier and precise optimization of ADA dosing by predicting trough levels at any time during the therapy cycle. Optimized dosing to achieve target ADA concentrations and low clearance is crucial to mitigate therapy discontinuation and active disease in IBD patients.
Kainic Acid Pig Model of Hippocampal Epilepsy
Mívalt, Filip , Maltais, Daniela D., Kim, Inyong , Began, Patrik, Lopez, Andrea Duque , Krakorova, Veronika, Winter, Bailey , Kuo, Cheng Yen, Sharma, Shelja, Harty, Elizabeth S., Kim, Luke H., Gregg, Nicholas, Montonye, Dan , Gow, Christopher, Miller, Kai J. , Leyde, Kent, Chang, Su-Youne , Gregg, Nicholas M. , Kremen, Vaclav , Gregg, Nicholas M , Duque Lopez, Andrea M , Mivalt, Filip , Kim, Jiwon W. , Kuo, Cheng Yen, Sharma, Shelja, Harty, Elizabeth S., Kim, Luke H., Montonye, Dan , Gompel, Jamie J. Van , Křemen, Václav , Worrell, Gregory A.

Mayo Clinic

No container title available | January 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.22.634312 | PMID 39896655 Get It

Abstract Translational large-animal models that can accommodate human-scale implantable devices are essential for advancing neuromodulation therapies in epilepsy. This study establishes a kainic acid (KA)-induced porcine model of mesial temporal lobe epilepsy (mTLE) using clinical imaging, stereotactic surgery, and a fully implantable neural stimulation and recording (INSR) device designed for humans. Seven pigs (six KA-treated and one saline control) underwent MRI-guided stereotactic implantation of electrodes targeting bilateral hippocampus (HPC) and anterior thalamus (ANT), followed by intra-hippocampal KA or saline infusion. Local field potentials (LFP) were recorded continuously with synchronized video monitoring. Seizures and LFP interictal epileptiform-like discharges (IEDs) were quantified using validated automated detectors. Histology was performed in the saline control and the longest surviving KA-treated pig. Intra-hippocampal KA infusion induced acute status epilepticus in all (6/6) treated pigs. Four animals survived to chronic monitoring with spontaneous seizures observed in three pigs (2,733 seizures; mean duration of 27.2 ± 17.6 seconds). IEDs were observed in bilateral HPC of all animals, including saline control, with higher rates in the lesioned HPC (p <0.0001). While the IED morphology is consistent with epileptiform activity; IEDs alone are not specific for epilepsy and physiological transients (e.g. sharp-wave ripples) and injury-related hyperexcitability or strain-specific hyperexcitability cannot be excluded. Histological analysis revealed patchy neuronal loss and cytoarchitectural changes in HPC. This porcine model reproduces electrophysiological features of human mTLE. This approach provides a powerful translational bridge for developing and testing next-generation INSR and neuromodulation strategies in freely behaving large animals.
Rethinking the residual approach for estimating cognitive resilience and resistance to AD pathology
Cuppels, Madison, Klinger, Hannah M , Langford, Oliver , Chhatwal, Jasmeer P. , Price, Julie C. , Properzi, Michael J , Amariglio, Rebecca E. , Johnson, Keith A. , Mukherjee, Shubhabrata , Resnick, Susan M. , Tunali, Ilke, Landau, Susan , Lockhart, Samuel N. , Birkenbihl, Colin J. , Boyle, Rory , Coughlan, Gillian , Schultz, Aaron P. , Rentz, Dorene M. , Gottesman, Rebecca F. , Maruff, Paul , Lim, Yen Ying , Masters, Colin L. , Beiser, Alexa , Burnham, Samantha C. , Cohen, Ann D. , Johnson, Sterling C. , Betthauser, Tobey J. , Seshadri, Sudha , Lockhart, Samuel N. , O’Bryant, Sid E. , Vemuri, Prashanthi , Sperling, Reisa Anne , Hohman, Timothy J. , Donohue, Michael , Buckley, Rachel F.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.094824 Get It

AbstractBackgroundThe residual approach has found wide application in researching cognitive resilience, a phenomenon conceptually understood as cognitive performance being better‐than‐typical for an individual, despite apparent AD pathology. The standard residual approach extracts information about an individual’s resilience from the residuals of a linear model predicting cognition. This approach is subject to several limiting assumptions. Here, we explore the implications of these assumptions and propose an alternative predictive modeling approach which circumvents them.MethodsOur alternative approach relies on training a machine learning model on a sample of participants who follow a “typical” clinical progression (Fig. 1A). Residuals are then extracted for a heterogeneous dataset that potentially includes resilient participants by comparing observed cognitive outcomes to those predicted by the “typical” model (Fig. 1B). Additionally, our estimate can be refined by effectively estimating and removing model error from the extracted residual by leveraging a second predictive model (Fig. 1C). Using simulated data, we explore the assumptions made by the standard approach and the consequences of their violation. We then contrast this against our approach.ResultsOur simulations demonstrated that the standard residual approach only extracted accurate resilience estimates if the predictors used in the model explained cognition sufficiently well, while being unrelated to resilience itself. That is, as the predictors explain more of the resilience, the residuals became increasingly determined by model error (Fig. 2). We found that residuals achieved with our approach are more precise and provide individualized estimates that are unaffected by the aforementioned trade‐off (Fig. 3).ConclusionsOur approach holds several advantages over the standard approach: The definition of resilience can be freely adjusted and enforced via different definitions of “typical”, it allows for incorporating complex, non‐linear models without removing relevant information from the residual, the error component of the residual can be estimated through cross‐validation, and all predictors that potentially explain cognition can be included into the model without losing resilience information from the residual. Our approach can be used to measure any phenomenon that can be operationalized as a deviation from a typical outcome and, thus, is also applicable for researching resistance to pathology.
Ethical Use of Cadaveric Images in Anatomical Textbooks, Atlases, and Journals: A Consensus Response From Authors and Editors
Kim, Hee‐Jin , Logan, Bari M., Hutchings, R. T., Anand, Mahindra , Burns, Danny, Singh, Vishram, Peris‐Celda, Maria , Martı́nez-Soriano, Francisco, Apaydın, Nihal, Hanna, Amgad S. , Yoshioka, Nobutaka , Fernandez‐Miranda, Juan C. , Saremi, Farhood , Spratt, Jonathan D., Ho, Siew Yen , Mori, Shumpei , Komune, Noritaka , Watanabe, Koichi , Abrahams, Peter, Ibaragi, Soichiro , Loukas, Marios , Tubbs, R. Shane, Kim, Hee-Jin , Hur, Mi-Sun , Reina, Francisco , Tabira, Yoko , Carrera, Anna , Komune, Noritaka , Watanabe, Koichi , Reina, Miguel Angel , Loukas, Marios , Iwanaga, Joe , Akita, Keiichi , Ottone, Nicolás Ernesto , Nonaka, Yoichi , Shoja, Mohammadali M. , Tabira, Yoko , Prats‐Galino, Alberto , Andrés, José De , Reina, Miguel Ángel , Anderson, Robert Henry

Mayo Clinic

Clinical Anatomy | January 4, 2025 | Volume: 38 | Issue: 2 | Pages: 222-225

10.1002/ca.24258 | PMID 39754475 Get It

ABSTRACT Nowadays, consent to use donor bodies for medical education and research is obtained from the body donors and their families before the donation. Recently, the International Federation of Associations of Anatomists (IFAA) published guidelines that could restrict the appearance of cadaveric images in commercial anatomical resources such as textbooks and other educational products. These guidelines state that the donor must expressly consent to using such images for this purpose. Cadaveric photos and drawings made from dissections of cadavers have been used in anatomy textbooks and atlases for hundreds of years. They are invaluable for anatomy students and clinical/surgical practitioners. The IFAA guidelines should not restrict the use of those older books; to do so would infringe the rights of those seeking knowledge from these resources. As the images in such textbooks and atlases are anonymized and are used for teaching and research, and the donors and their families are informed about this before the donation, we believe no additional consent is needed. It is impossible to separate educational from “commercial” usage entirely in any situation, e.g., publications from publishers and the use of cadavers in medical schools. Therefore, our best efforts to avoid unethical use of cadaveric images by following traditional consent processes are still needed so that more people will reap the benefits from them. As senior textbook/atlas authors/editors from over 10 countries, we believe that using cadaveric images in anatomy textbooks is appropriate, and no additional consent should be necessary. Such usage falls within the good faith of professionals using these invaluable gifts.
Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer
Cathcart-Rake, Elizabeth , Chan, Alexandre , Menendez, Alvaro G. , Markstrom, Denise, Schnitzlein, Carla W., Chong, Yohana Geomar Macías Yen , Dizon, Don S. , Cathcart-Rake, Elizabeth J , Chong, Yee Won

Mayo Clinic

CA: A Cancer Journal for Clinicians | December 9, 2024 | Volume: 75 | Issue: 1 | Pages: 68-81

10.3322/caac.21872 | PMID 39652385 Get It

Abstract In the United States, over 2 million individuals openly identify with a gender that differs from their sex assigned at birth. A cancer diagnosis is physically and psychologically taxing—and, in some, traumatic. However, for transgender and gender‐diverse (TGD) people, many of whom have experienced discrimination in myriad health care settings, the challenges may be even greater. These recommendations focus on how best to deliver quality cancer care to transgender men (individuals who identify as men but were assigned female sex at birth), transgender women (individuals who identify as women but were assigned male sex at birth), and people who identify somewhere beyond this gender spectrum as nonbinary or using other terms, based on the available, albeit sparse, literature. This review broaches: (1) the epidemiology of cancer in TGD individuals, including the incidence of cancer and cancer‐related mortality; (2) cancer center practices that are welcoming and affirming to TGD patients; (3) the need for awareness and intentionality in the spaces of diagnosis and treatment for cancer; (4) the inevitable conclusion that gender differences exist but much more needs to be learned about the impact of gender‐affirming therapy, consisting of gender‐affirming surgeries and gender‐affirming hormone therapy, on cancer therapy; and (5) the efficacy and perceived safety of antineoplastic therapy and gender‐affirming hormone therapy.